Skip to main content

Table 1 Demographics and baseline characteristics of the study population (FAS Year 5 , N = 377)

From: Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

Parameter

Treatment group

 

Placebo n = 133

300IR (2 M) n = 117

300IR (4 M) n = 127

Total N = 377

Gender, n (%)

    

 Male

79 (59.4)

71 (60.7)

81 (63.8)

231 (61.3)

 Female

54 (40.6)

46 (39.3)

46 (36.2)

146 (38.7)

Age, years

    

 n

133

117

127

377

 Mean (SD)

30.1 (8.7)

30.9 (7.8)

30.5 (8.5)

30.5 (8.3)

 Range

18–49

18–51

18–49

18–51

Body mass index, kg/m 2

    

 n

132

117

127

376

 Mean (SD)

23.9 (4.3)

24.3 (3.9)

24.2 (3.7)

24.1 (4.0)

 Range

15.6–42.4

17.3–35.1

17.2–35.1

15.6–42.4

Duration of ARC, years

    

 n

133

117

127

377

 Mean (SD)

12.5 (9.0)

12.9 (8.8)

13.0 (9.2)

12.8 (9.0)

 Range

1.6–44.0

1.5–39.0

1.5–42.1

1.5–44.0

RRTSS

    

 n

133

117

127

377

 Mean (SD)

14.0 (1.7)

13.9 (1.8)

14.2 (1.7)

14.1 (1.7)

 Range

12–18

12–18

12–18

12–18

Asthma status, n (%)

    

 Yes

19 (14.3)

13 (11.1)

16 (12.6)

48 (12.7)

 No

114 (85.7)

104 (88.9)

111 (87.4)

329 (87.3)

Sensitization status, n (%)

    

 Monosensitized

53 (39.8)

47 (40.2)

53 (41.7)

153 (40.6)

 Polysensitized

80 (60.2)

70 (59.8)

74 (58.3)

224 (59.4)

  1. 2 M, 2-month preseasonal dosing protocol; 4 M, 4-month preseasonal dosing protocol; ARC, allergic rhinoconjunctivitis; FAS, full analysis set; IR, index of reactivity; RRTSS, retrospective rhinoconjunctivitis total symptom score; SD, standard deviation.